Simplify Health Care ETF vs. VanEck Biotech ETF: One Critical Difference Could Shape Future Returns
The healthcare sector presents investors with a wide range of opportunities, but not all healthcare ETFs are positioned to capitalize on them equally. Differences in portfolio concentration and investment strategy can significantly influence how these funds perform as market conditions evolve.
The Simplify Health Care ETF (PINK +0.32%) takes an actively managed approach, investing across multiple healthcare industries, while the VanEck Biotech ETF (BBH +0.21%) tracks a concentrated index of 25 biotechnology companies.
Although both funds provide exposure to healthcare, their contrasting investment strategies create meaningful differences in diversification, risk, and growth potential. Here’s how they compare and which could be better positioned heading into 2027.
Snapshot (cost & size)
MetricBBHPINKIssuerVanEckSimplifyShare price$254.50 (as of 2026-11-02)$40.08 (as of 2026-11-02)Expense ratio0.35%0.51%1-yr return (as of 2026-11-02)41.2%21.1%Dividend yield0.37%0.7%Beta0.700.72AUM$536.37 million$350.56 million
VanEck Biotech ETF is the more affordable option with an expense ratio of 0.35%, which is notably lower than the category average for specialty funds. Simplify Health Care ETF carries a higher 0.51% fee but offers a larger trailing-12-month dividend yield of 0.7%.
Performance & risk comparison
MetricBBHPINKMax drawdown (5 yr)(34.6%)(18.7%)Growth of $1,000 over 5 years (total return)$1,285$1,554
What’s inside
The Simplify Health Care ETF (PINK +0.32%) takes an actively managed approach, investing across healthcare subsectors including biotechnology, pharmaceuticals, medical devices, and healthcare services. Approximately 90% of its portfolio is allocated to healthcare stocks, with smaller positions in consumer discretionary, materials, and industrial companies.
The fund holds approximately 52 positions, with its largest investments including United Therapeutics (UTHR +1.20%) at 8.45%, Arcutis Biotherapeutics (ARQT +3.63%) at 8.42%, and Johnson & Johnson (JNJ -0.13%) at 7.58%. Launched in 2021, the ETF also has a unique charitable component, with Simplify pledging its net profits from the fund to the Susan G. Komen foundation. Over the trailing 12 months, the fund has distributed approximately $0.30 per share, representing a yield of roughly 0.7%.
The VanEck Biotech ETF (BBH +0.21%) takes a more concentrated approach, tracking the MVIS US Listed Biotech 25 Index. The fund invests exclusively in biotechnology companies, with just 25 holdings and no exposure to other sectors. This narrow focus makes its performance particularly sensitive to developments in the biotechnology industry and the performance of its largest holdings.
The fund’s top positions include Amgen (AMGN +0.62%) at 16.56%, Gilead Sciences (GILD -0.67%) at 14.36%, and Vertex Pharmaceuticals (VRTX -0.16%) at 8.19%. Together, these three companies account for nearly 40% of the portfolio, highlighting its substantial concentration in established biotechnology leaders. Launched in 2011, the fund has distributed $0.96 per share over the trailing 12 months, representing a dividend yield of approximately 0.37% at its recent share price of $254.50.
For more guidance on ETF investing, check out the full guide at this link.
Collapse
BBH & PINK: Performance Comparison
Key Financial Metrics
BBH – VanEck ETF Trust – VanEck Biotech ETF
$257.79
+0.21% (+$0.55)
PINK – Simplify Exchange Traded Funds – Simplify Health Care ETF
$40.76
+0.32% (+$0.13)
52wk Range
$179.25 – $263.74
Dividend & Yield
$0.96 (0.37%)
52wk Range
$32.03 – $41.20
Dividend & Yield
$0.30 (0.74%)
BBH – VanEck ETF Trust – VanEck Biotech ETF
$257.79
+0.21% (+$0.55)
52wk Range
$179.25 – $263.74
Dividend & Yield
$0.96 (0.37%)
PINK – Simplify Exchange Traded Funds – Simplify Health Care ETF
$40.76
+0.32% (+$0.13)
52wk Range
$32.03 – $41.20
Dividend & Yield
$0.30 (0.74%)
Which looks like the better buy
The healthcare sector faces a mixed outlook heading into 2027. Expanding demand for innovative treatments and a potential resurgence in biotechnology mergers and acquisitions present opportunities for investors. However, growing pressure on drug prices, patent expirations, and uncertainty surrounding interest rates could create significant differences in performance across the industry.
Against this backdrop, the VanEck Biotech ETF looks like the better buy. Its concentration in established biotechnology leaders provides exposure to companies with established revenue streams, substantial research budgets, and the financial resources to navigate industry headwinds. The fund’s lower expense ratio also provides a long-term cost advantage.
The Simplify Health Care ETF offers greater flexibility to capitalize on opportunities across healthcare subsectors, but its active management introduces additional stock-selection risk and higher fees. While VanEck’s concentrated portfolio isn’t immune to risks, I favor its exposure to established biotechnology leaders with diversified drug portfolios, substantial financial resources, and the ability to capitalize on emerging opportunities across the industry.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 835%* — a market-crushing outperformance compared to 208% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of November 12, 2026.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.